Mobia Medical, Inc.
Mobia Medical, Inc. is a U.S.-based medical device company focused on stroke recovery. Its core product is the Vivistim Paired Vagus Nerve Stimulation System, which is used to support therapy for chronic ischemic stroke survivors with upper-extremity motor impairment.
Business
Share of revenueImplantable neurostimulation system used in stroke rehabilitation therapy.
Consumable and replacement items sold alongside the installed base.
Customers
The company sells primarily to primary and comprehensive stroke centers in the United States, where the Vivistim System is implanted and used in patient care. These hospitals typically buy an initial stocking order and then reorder replenishment product as procedures are performed. Adoption also depends on physicians, therapy sites, and payer coverage because the therapy is tied to post-stroke rehabilitation pathways.
Hospitals that perform most Vivistim implants and buy the system for stroke recovery programs.
Higher-acuity stroke hospitals that adopt the system for eligible chronic stroke patients.
Buying groups that negotiate pricing and contract access for affiliated hospitals and ASCs.
Facilities that support post-implant rehabilitation and help drive therapy utilization.
Private and governmental payors that influence adoption through reimbursement coverage.
Strategy
The company is focused on expanding commercial reach, adding stroke centers, and increasing awareness of Vivistim Therapy among clinicians and patients. It also seeks broader payer coverage and continued clinical and regulatory work to support adoption of the therapy. Because the business is concentrated in a specialized hospital channel, execution depends on scaling the sales organization efficiently and maintaining supply continuity.
The product is sold into a concentrated hospital channel, so more field coverage can increase implants and reorders.
Coverage policies directly affect hospital willingness to adopt and patients' access to therapy.
Clinical validation and regulatory compliance reinforce adoption in a specialized medical device market.
Third-party manufacturing must keep pace with demand and quality requirements.
Geography
Mobia Medical generates substantially all of its revenue in the United States, where it sells the Vivistim System to stroke centers. Its commercial footprint is built around concentrated high-volume stroke hospitals and the surrounding rehabilitation network, so U.S. reimbursement and hospital contracting are central to the business. The company also relies on third-party manufacturers and suppliers, which adds operational exposure even though end-market sales are domestic.
Risks
Mobia Medical faces commercialization risk because adoption depends on hospital contracting, reimbursement, and clinician awareness in a narrow stroke-care market. It also relies on third-party manufacturers and suppliers, which creates quality, supply, and continuity risk if components or finished goods are delayed or unavailable. As a medical device company, it is also exposed to competitive pressure, technological change, and ongoing losses while it scales.
- Reimbursement and coverage riskImpact: HighLikelihood: High
Adoption depends on payer policies for procedures using Vivistim.
Exposure: Private and governmental payors
- Ongoing losses and capital needsImpact: HighLikelihood: High
Commercial expansion, clinical work, and public-company costs can require additional funding.
Exposure: Growth-stage medical device commercialization
- GPO and IDN contracting pressureImpact: HighLikelihood: Medium
Buying groups negotiate category-by-category and can force lower prices or fewer vendors.
Exposure: U.S. hospital channel
- Third-party manufacturing and supplier dependenceImpact: HighLikelihood: Medium
Single-source or limited suppliers can delay shipments, raise costs, or cause recalls.
Exposure: Contract manufacturers and component suppliers
- Competitive and technology riskImpact: MediumLikelihood: Medium
Larger medical device and robotics companies have greater scale, resources, and relationships.
Exposure: Stroke prevention and stroke care markets
Accounting
Judgemental itemsManagement identifies these as the most critical estimates, and they can materially affect expense and equity.
Impact: Reported operating expenses and equity valuation
Initial stocking orders and replenishment sales can shift between quarters.
Impact: Quarterly revenue comparability
Office and warehouse leases create fixed commitments and lease liabilities.
Impact: Balance sheet and operating expense recognition
Fair value remeasurement can create non-cash gains or losses in other income.
Impact: Net income volatility
Non-cancelable commitments affect liquidity and inventory planning.
Impact: Cash flow and working capital
Similar listed companies
Publicly listed companies with a comparable business focus.
LivaNova PLC
LIVN · Electromedical & Electrotherapeutic Apparatus
LivaNova PLC is a medical technology company focused on therapies for cardiac and neurological conditions.
Penumbra Inc
PEN · Surgical & Medical Instruments & Apparatus
Penumbra is a U.S.-based medical device company focused on thrombectomy and related interventional therapies for removing blood clots from the body.
Vycor Medical Inc
VYCO · Surgical & Medical Instruments & Apparatus
Nexstim Plc
NXTMH · Medical Devices
Nexstim is a Finnish medical technology company focused on developing non-invasive brain stimulation technologies.
Inspire Medical Systems, Inc.
INSP · Surgical & Medical Instruments & Apparatus
Inspire Medical Systems develops and commercializes a minimally invasive neurostimulation therapy for obstructive sleep apnea.
Neuraxis, INC
NRXS · Electromedical & Electrotherapeutic Apparatus
Neuraxis, INC is a U.S.-based medical device company focused on neuromodulation therapies for pediatric and adult patients.
Last updated: 24/09/2026